



Clinical Trial Research Participants Needed for a Cushing Disease Study

Treatment of Cushing Disease With Seliciclib

Who? We are looking for men or women, aged 18 and older, with:

- Pituitary ACTH-producing tumor causing Cushing disease, including newly diagnosed Cushing disease or recurrent or persistent Cushing disease despite standard treatment
- Persistently elevated urinary cortisol levels

What? Seliciclib (also known as roscovitine) is an investigational medication that is not FDA approved. It is administered orally for 4 days every week for 4 weeks at one of 3 doses/schedules being studied. You will be required to participate in 7 clinic visits, including a screening visit, a baseline visit, weekly visits while on drug treatment, and a final visit at study completion. Routine history and physical with blood, urine tests, ECG, visual field test, and pituitary MRI will be obtained during the visit.

Where? All testing and treatment will be done at:

Pituitary Center at Cedars-Sinai Medical Center, AHSP Building (A6600)
127 S. San Vicente, Los Angeles, CA 90048

Compensation? You will receive a meal voucher and parking validation at each study visit.

If you or someone you know may be interested in learning about this study, please contact Pituitary Center Research Office at (424) 315-4489.

For more information about this study, visit <https://clinicaltrials.gov/ct2/show/NCT03774446>

For More Information:

Vivian Hwe, CCRP
Tel: (424) 315-4489
Email: Vivian.Hwe@cshs.org
Cedars-Sinai Medical Center



CEDARS-SINAI®

Clinical Trial Identifier: NCT03774446
Funded by FDA Office of Orphan Products Development
Investigators: Shlomo Melmed, MD, and Ning-Ai Liu, MD, PhD